Kenneth Galbraith - 12 Jan 2026 Form 4 Insider Report for Zymeworks Inc. (ZYME)

Reporting relationship: Chair & CEO, Director
Issuer ticker: ZYME
Reported as of: 12 Jan 2026
Net transaction value: -$689,819
SEC form: 4
Accepted by SEC: 12 Jan 2026, 19:07:56 UTC
Prior SEC filing: 05 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Daniel Dex, Attorney-in-Fact

Key filing fact

Kenneth Galbraith filed Form 4 for Zymeworks Inc. (ZYME) on 12 Jan 2026.

Key facts

This page summarizes Kenneth Galbraith's Form 4 filing for Zymeworks Inc. (ZYME).
6 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 12 Jan 2026, 19:07.

Change

Previous filing in this sequence was filed on 05 Jan 2026.
Current net transaction value: -$689,819.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001567045 Primary reporting owner

Galbraith Kenneth

Relationship: Chair & CEO, Director
Address: C/O ZYMEWORKS INC., 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN
Signature: /s/ Daniel Dex, Attorney-in-Fact
Signature date: 12 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ZYME transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +64,000
Change %: +33%
Price: $0.000000
Shares after: 257,266
Date: 12 Jan 2026
Ownership: Direct
Footnotes: F1

ZYME transaction

Common Stock

Sale

Transaction value: $689,819
Shares: -30,424
Change %: -12%
Price: $22.67
Shares after: 226,842
Date: 12 Jan 2026
Ownership: Direct
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZYME transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value: $0
Shares: -64,000
Change %: -33%
Price: $0.000000
Shares after: 128,000
Date: 12 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 64,000
Exercise price
Footnotes: F4, F5

ZYME transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +216,000
Change %
Price: $0.000000
Shares after: 216,000
Date: 12 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 216,000
Exercise price: $23.16
Footnotes: F6

ZYME transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +144,000
Change %
Price: $0.000000
Shares after: 144,000
Date: 12 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 144,000
Exercise price
Footnotes: F4, F7

ZYME transaction Derivative

Performance Stock Unit

Award

Transaction value: $0
Shares: +222,000
Change %
Price: $0.000000
Shares after: 222,000
Date: 12 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 222,000
Exercise price
Footnotes: F8, F9

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 9 footnotes

Footnote F1

Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 10, 2025.

Footnote F2

Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.

Footnote F3

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.49 to $23.05, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Footnote F4

Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of common stock.

Footnote F5

The RSUs were granted on January 10, 2025 and vest in three equal annual installments beginning on the first anniversary of grant date.

Footnote F6

Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date.

Footnote F7

RSUs vest in four equal annual installments beginning on first anniversary of grant date.

Footnote F8

Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 111,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index. The PSUs will only vest at the end of the three-year performance period if the reporting person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals,

Footnote F9

(Continued from footnote 8) except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control).